Our DR:EAM
OcuTerra is working to improve the standard of care for patients living with Diabetic Retinopathy through the DR:EAM clinical trial.
What is a Clinical Trial?
Clinical trials are research studies that evaluate potential treatments or other interventions for disease. All investigational treatments must be tested in clinical trials before they can be approved and prescribed to patients. Volunteer participation is an integral part of clinical trials, helping to make the eventual approval of treatments possible.
Our DR:EAM Clinical Trial
DR:EAM is a Phase 2 multicenter, randomized, double-masked, vehicle-controlled clinical trial designed to assess the safety and efficacy of a high and low dose of daily topical administration of OTT166, OcuTerra’s investigational RGD integrin inhibitor in certain adults with diabetic retinopathy.
Trial Details
The clinical trial will enroll approximately 200 adult patients with type I/II diabetes and moderately severe to severe non-proliferative diabetic retinopathy (NPDR) or mild proliferative diabetic retinopathy (PDR) with minimal vision loss who have not received prior treatment for DR.
For Patients
The DR:EAM study: A new clinical trial for eligible patients with diabetic retinopathy
For Physicians
DR:EAM: a study of OTT166, a novel investigational candidate for the potential treatment of diabetic retinopathy
